| Bioactivity | Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia[1]. Avarofloxacin (JNJ-Q2) is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC90 value[2]. Avarofloxacin (JNJ-Q2) has potential for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections[3]. | ||||||||||||
| Name | Avarofloxacin | ||||||||||||
| CAS | 878592-87-1 | ||||||||||||
| Formula | C21H23F2N3O4 | ||||||||||||
| Molar Mass | 419.42 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Avarofloxacin
CAS: 878592-87-1 F: C21H23F2N3O4 W: 419.42
Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.